There’s a new obesity pill in town, and it doesn’t mess around with your muscles.
It’s called SANA, and it’s an oral drug developed by Eolo Pharma, a biotech firm aiming to change how we treat obesity. In a world dominated by injectables like Ozempic and Wegovy—which often cause people to lose precious lean muscle—SANA is flipping the script.
The Science Is Hot
SANA is the first drug to trigger creatine-dependent thermogenesis in humans. That’s a fancy way of saying it activates a pathway in your body that burns energy—without needing a crazy diet or exercise plan.
Unlike GLP-1 drugs that mainly suppress appetite, this pill burns fat while keeping your muscle intact. In some preclinical tests, it even boosted lean muscle mass. Yes, you read that right.
According to EchoMRI scans (a fancy way to measure fat and muscle), people on SANA were shedding fat while keeping, or even gaining, muscle.
Also Read Biocon Poised to Dominate Diabetes-Obesity Space, Says Kiran Mazumdar-Shaw
Early Human Trials Show Promise
In a double-blind, placebo-controlled Phase 1a/b trial, people with obesity took the obesity pill SANA every day for just 15 days. The result? Noticeable weight loss in just two weeks. That’s fast.
More importantly, no major side effects popped up. And guess what didn’t drop? Their muscle mass.
This is a big deal. Why? Because other drugs like Ozempic are linked to muscle wasting, which can be dangerous, especially as you age.
What’s Next for SANA?
Eolo Pharma isn’t slowing down. They’re kicking off Phase 2 trials this year. These tests will look at SANA as both a solo treatment and a combo therapy—likely paired with other obesity meds or lifestyle plans.
And if those results go well, we might finally have a pill-based fat-burning alternative that’s safer, smarter, and easier to take than the injectables dominating the market.
Why This Could Be a Game-Changer
Let’s face it—losing weight is hard. Pills that make it easier are welcome. But most of today’s options come with tradeoffs: lose fat, but also lose muscle. That’s not a win.
SANA changes the conversation. It’s an obesity pill that fights fat, not your body.
If it holds up in larger trials, this could become a serious competitor to Ozempic and others—no needles, no muscle loss, just results.
Also Read AstraZeneca’s Masterstroke! $5.3B AI Deal with China’s CSPC Shakes Big Pharma
